IRLAB publishes information document in connection with the rights issue
IRLAB Therapeutics AB (“IRLAB” or the “Company”) have prepared an information document (the “Information Document”) in connection with the rights issue of shares of series A resolved by the Board of Directors on 24 June 2025 (the “Rights Issue”). The information document is available on the Company’s website, www.irlab.se. The information document will also be made available on Eminova Fondkommission AB’s website, www.eminova.se.
THIS PRESS RELEASE MAY NOT BE MADE PUBLIC, PUBLISHED OR DISTRIBUTED, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, BELARUS, CANADA, HONG KONG, JAPAN, NEW ZEELAND, SINGAPORE, SOUTH AFRICA, SOUTH KOREA, SWITZERLAND, RUSSIA, OR ANY OTHER JURISDICTION IN WHICH SUCH ACTIONS, WHOLLY OR IN PART, WOULD BE UNLAWFUL OR DEMAND ADDITIONAL REGISTRATION OR OTHER MEASURES. PLEASE REFER TO “IMPORTANT INFORMATION” IN THE END OF THIS PRESS RELEASE.
IRLAB Therapeutics AB (“IRLAB” or the “Company”) have prepared an information document (the “Information Document”) in connection with the rights issue of shares of series A resolved by the Board of Directors on 24 June 2025 (the “Rights Issue”). The information document is available on the Company’s website, www.irlab.se. The information document will also be made available on Eminova Fondkommission AB’s website, www.eminova.se.
On 24 June 2025 the Board of Directors of the Company resolved to carry out a rights issue of shares of series A of a maximum of approximately SEK 136 million with preferential rights for existing shareholders. Complete information, terms and conditions regarding the Rights Issue are set out in the Information Document. The Information Document is available on IRLAB's website, www.irlab.se, and will also be made available on Eminova Fondkommission AB's website, www.eminova.se.
The Information Document
In connection with the Rights Issue, the Company has prepared the Information Document in accordance with Article 1.4 db) of Regulation (EU) 2017/1129 of the European Parliament and of the Council of 14 June 2017 on the prospectus to be published when securities are offered to the public or admitted to trading on a regulated market, and repealing Directive 2003/71/EC, as amended (the “Prospectus Regulation”). The Information Document has been prepared in accordance with the requirements of appendix IX of the Prospectus Regulation. The information document has been registered with the Swedish Financial Supervisory Authority, but the Swedish Financial Supervisory Authority has not reviewed or approved the Information Document.
Indicative time plan
The following time plan for the Rights Issue is preliminary and subject to change.
Trading in subscription rights | 3 July 2025 – 14 July 2025 |
Subscription period | 3 July 2025 – 17 July 2025 |
Trading in paid subscribed shares (BTA) | 3 July 2025 – week 31, 2025 |
Expected day for announcement of the outcome | 21 July 2025 |
Advisers
MAQS Advokatbyrå AB is legal advisor and Zonda Partners AB acts as financial advisor to the Company in connection with the Rights Issue. Eminova Fondkommission AB is issuing agent in connection with the Rights Issue.